Fulvestrant Ever Pharma Dosage & Drug Information

Concise Prescribing Info

Contents

Fulvestrant

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

Estrogen receptor +ve, locally advanced or metastatic breast cancer in postmenopausal women not previously treated w/ endocrine therapy, or w/ disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. In combination w/ palbociclib for hormone receptor +ve, human epidermal growth factor receptor 2 -ve locally advanced or metastatic breast cancer in women w/ disease progression after endocrine therapy.

Dosage/Direction for Use

IM Adult female (including elderly) 500 mg at intervals of 1 mth as 2 consecutive 5 mL slow IM inj (1-2 min/inj), 1 in each buttock (gluteal area), w/ an additional 500 mg given 2 wk after the initial dose.

Contraindications

Hypersensitivity. Severe hepatic impairment. Pregnancy & lactation.

MIMS Class

Cancer Hormone Therapy

ATC Classification

L02BA03 - fulvestrant ; Belongs to the class of anti-estrogens. Used in treatment of neoplastic diseases.

Regulatory Classification

POM

Presentation/Packing

Form

Fulvestrant Ever Pharma Solution for injection 250 mg/5 mL

Packing/Price

1's

Fulvestrant Ever Pharma

fulvestrant

Manufacturer:

EVER Pharma